InsidersTradesSigma
Total declarations
Company
▲ Purchases (2 ops.)
▼ Sales (0 ops.)
Insider track record
ExecutiveDisclosed buys
2
Disclosed sells
0
T+90 hit rate
75%
T+90 mean return
+21.5%
Across 4 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Discover the full record of transactions filed by Danahy Kevin Patrick, Directeur Commercial. Insider active across 1 company, notably Pulse Biosciences, INC.. Aggregated, 9 reports have been recorded. Breakdown: 2 buys · 0 sell. Total volume traded: €44k. History available since 30 September 2022. The latest transaction was filed on 12 February 2026 (Levée d'options). Regulator: SEC (Form 4). All data is openly available.
Declarations9 total
20,000 shares@ US$1.5322.3% of flowCommon StockSEC:0001437749-26-004438
20,000 shares@ US$1.530.0015% mcap22.3% of flowCommon StockSEC:0001437749-26-004438:0
20,000 shares@ US$1.5322.4% of flowCommon StockSEC:0001437749-26-003840
20,000 shares@ US$1.530.0015% mcap22.4% of flowCommon StockSEC:0001437749-26-003840:0
4,600 shares@ US$1.535.2% of flowCommon StockSEC:0001437749-25-030665
4,600 shares@ US$1.530.0004% mcap5.2% of flowCommon StockSEC:0001437749-25-030665:0
650 sharesCommon StockSEC:0001437749-24-022356:0
4,781 shares@ US$6.519918.0% of flowCommon StockSEC:0001437749-23-032410:0
Ideal exit: 12 Aug 2024 (T+270)
6,500 shares@ US$2.309.6% of flowCommon StockSEC:0001839882-22-022698:0
Ideal exit: 27 Jun 2023 (T+270)
9 of 9 declarations
About Danahy Kevin Patrick
Danahy Kevin Patrick is the Chief Commercial Officer of PULSE BIOSCIENCES, INC. He oversees the business strategy and development of the company, which focuses on medical technologies. His role is essential in positioning PULSE as a leader in the health solutions sector.
